HER2-targeted therapies have long been targeted at patients with HER2-overexpressing BC, but with the development and exploration of novel HER2-targeted antibody−drug conjugates (ADCs), patients with low HER2 expression BC can also benefit from them (9, 10). The gene discussed is ERBB2; the disease is breast cancer.